Candriam S.C.A. Morphic Holding, Inc. Transaction History

Candriam S.C.A.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 05, 2024	SELL	$26.12 - $34.07 $934,547 - $1.22 Million	-35,779 Reduced 14.32%	214,154 $7.3 Million
Q2 2023 Aug 08, 2023	SELL	$34.33 - $62.11 $1.71 Million - $3.1 Million	-49,850 Reduced 16.63%	249,933 $14.3 Million
Q1 2023 May 12, 2023	SELL	$26.01 - $48.69 $1.17 Million - $2.2 Million	-45,150 Reduced 13.09%	299,783 $11.3 Million
Q2 2022 Aug 03, 2022	BUY	$19.74 - $43.01 $3.17 Million - $6.9 Million	160,537 Added 87.06%	344,933 $7.49 Million
Q1 2022 May 13, 2022	BUY	$36.25 - $52.02 $6.68 Million - $9.59 Million	184,396 New	184,396 $7.4 Million

4.7M

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $2.19B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.